Phase II Study of FCN-159 in NF2 Nerve Sheath Tumors

Cannot have received: pharmaceutical or biological therapy

Pharmaceutical or biological therapy within 3 weeks or 5 half-lives prior to enrollment, whichever is longer

Cannot have received: growth factors

Use of growth factors that promote platelet, red blood cell, or white blood cell count or function within 7 days prior to enrollment

Cannot have received: major surgery

Patients who have received major surgery or anti-tumor immunotherapy within 4 weeks prior to enrollment

Cannot have received: anti-tumor immunotherapy

Patients who have received major surgery or anti-tumor immunotherapy within 4 weeks prior to enrollment

Cannot have received: radiation therapy

Radiation therapy for nerve sheath tumors within 4 weeks prior to enrollment

Cannot have received: corticosteroids (dexamethasone)

Dose adjustment for patients treated with dexamethasone or other corticosteroids within 1 week prior to enrollment

Cannot have received: interventional clinical trial

Patients who have participated in another interventional clinical trial within 4 weeks prior to enrollment

Cannot have received: MEK inhibitor (Selumetinib)

Prior treatment with Selumetinib or any other MEK 1/2 inhibitor